Immune Thrombocytopenia (ITP) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
Immune Thrombocytopenia (ITP) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Immune Thrombocytopenia Market
The Immune Thrombocytopenia Market size was valued at USD 2.99 Billion in 2018, and is projected to reach USD 3.30 Billion by 2032, exhibiting a CAGR of 0.2% during the forecast period of 2024-2032.
The COVID-19 pandemic significantly impacted the ITP market by disrupting supply chains and delaying clinical trials and patient diagnosis. Many hospitals prioritized COVID-19 treatment, resulting in fewer ITP consultations and postponed treatments. Additionally, pandemic-induced stress increased the prevalence of autoimmune conditions, potentially influencing ITP cases. However, the use of immune-modulating therapies during COVID-19 spurred research into treatments with broader applications, indirectly benefiting the ITP market. As healthcare systems recover, demand for effective ITP treatments is expected to rise, driven by increased disease awareness and improved diagnostic facilities.
One notable trend in the ITP market is the growing adoption of personalized medicine and targeted therapies. Biopharmaceutical companies are developing drugs that target specific pathways involved in the disease, such as thrombopoietin receptor agonists (TPO-RAs) and anti-CD20 monoclonal antibodies. These treatments are designed to improve platelet counts while minimizing side effects, offering a patient-centric approach. Additionally, advancements in gene and cell therapy hold promise for more innovative solutions. This trend aligns with the increasing focus on precision medicine and reflects the industry’s commitment to addressing unmet needs in chronic ITP management.
The rising prevalence of immune thrombocytopenia globally is a key driving factor for the ITP market. Increasing awareness and early diagnosis of the disease have led to higher treatment rates, boosting market demand. Furthermore, advancements in research and development, supported by government funding and pharmaceutical investments, have resulted in more effective therapies entering the market. The growing geriatric population, which is more susceptible to autoimmune diseases, also fuels market growth. These factors, combined with a focus on developing treatments that improve patient outcomes, are driving the expansion of the ITP market.
Comprehensive Analysis of Immune Thrombocytopenia Market
The Immune Thrombocytopenia Market growth is rising at an exponential rate due to its marketplace segmentation. This market expansion correctly affords a detailed local assessments thinking about the dominant supply and call for forces that effect the enterprise. These segmentations are methodically segregated By type, by treatment, by distribution channel. By Type include Acute Immune Thrombocytopenia, Chronic Immune Thrombocytopenia. By Treatment include Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, Others. By Distribution Channel include Hospital Pharmacy, Retail Pharmacy, Others.
The North America region lead the Immune Thrombocytopenia Market share by benefitting a market size of USD 1.58 Billion Factors such as higher access to treatment of ITP, larger presence of key market players, advanced healthcare infrastructure, rising awareness of rare blood disorders are expected to positively influence immune thrombocytopenia market in North America.
The top players in the market play a crucial role in the industry assuring market growth and setting market standards. These players include, Google LLC (Alphabet, Inc.), Magic Leap, Inc., ReWalk Robotics, SAMSUNG, B-Temia, Panasonic Holdings Corporation, NVIDIA Corporation, Microsoft, Ekso Bionics, Vuzix,these market players provide a level-playing competitive landscape.
March 2018: Dova Pharmaceuticals, along with its wholly-owned subsidiary AkaRx, Inc. entered into a distribution and development rights agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. For DOPTELET in China and Hong Kong
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2015-2026
Base Year 2018
Forecast Period 2019-2026
Historical Period 2015-2017
Unit Value (USD Billion)
Segmentation By Type
Acute Immune Thrombocytopenia
Chronic Immune Thrombocytopenia
By Treatment
Thrombopoietin Receptor Agonist
Immunoglobulins
Corticosteroids
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Others
By Region/Country
North America (U.S. and Canada)
Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe)
Asia Pacific (Japan, China, India, South Korea, Australia, and Rest of Asia Pacific)
Latin America
Middle East and AfricaPlease Note: It will take 5-6 business days to complete the report upon order confirmation.
Table of Contents
212 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Immune Thrombocytopenia for Key Countries, 2018
- 4.2. Introduction of New Products / Approvals (by Major Players)
- 4.3. Recent Developments Mergers, Acquisitions and Partnerships
- 4.4. Pipeline Analysis
- 4.5. Patent Analysis
- 5. Global Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Type
- 5.2.1. Acute Immune Thrombocytopenia
- 5.2.2. Chronic Immune Thrombocytopenia
- 5.3. Market Analysis, Insights and Forecast – By Treatment
- 5.3.1. Thrombopoietin Receptor Agonists
- 5.3.2. Immunoglobulins
- 5.3.3. Corticosteroids
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast – By Country
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Type
- 6.2.1. Acute Immune Thrombocytopenia
- 6.2.2. Chronic Immune Thrombocytopenia
- 6.3. Market Analysis – By Treatment
- 6.3.1. Thrombopoietin Receptor Agonists
- 6.3.2. Immunoglobulins
- 6.3.3. Corticosteroids
- 6.3.4. Others
- 6.4. Market Analysis – By Distribution Channel
- 6.4.1. Hospital Pharmacy
- 6.4.2. Retail Pharmacy
- 6.4.3. Others
- 6.5. Market Analysis – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. U.S. Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Type
- 7.2.1. Acute Immune Thrombocytopenia
- 7.2.2. Chronic Immune Thrombocytopenia
- 7.3. Market Analysis – By Treatment
- 7.3.1. Thrombopoietin Receptor Agonists
- 7.3.2. Immunoglobulins
- 7.3.3. Corticosteroids
- 7.3.4. Others
- 7.4. Market Analysis – By Distribution Channel
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy
- 7.4.3. Others
- 8. Canada Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Type
- 8.2.1. Acute Immune Thrombocytopenia
- 8.2.2. Chronic Immune Thrombocytopenia
- 8.3. Market Analysis – By Treatment
- 8.3.1. Thrombopoietin Receptor Agonists
- 8.3.2. Immunoglobulins
- 8.3.3. Corticosteroids
- 8.3.4. Others
- 8.4. Market Analysis – By Distribution Channel
- 8.4.1. Hospital Pharmacy
- 8.4.2. Retail Pharmacy
- 8.4.3. Others
- 9. Europe Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Type
- 9.2.1. Acute Immune Thrombocytopenia
- 9.2.2. Chronic Immune Thrombocytopenia
- 9.3. Market Analysis – By Treatment
- 9.3.1. Thrombopoietin Receptor Agonists
- 9.3.2. Immunoglobulins
- 9.3.3. Corticosteroids
- 9.3.4. Others
- 9.4. Market Analysis – By Distribution Channel
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy
- 9.4.3. Others
- 9.5. Market Analysis – By Country
- 9.5.1. Germany
- 9.5.2. France
- 9.5.3. U.K.
- 9.5.4. Italy
- 9.5.5. Spain
- 9.5.6. Rest of Europe
- 10. Germany Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 10.1. Key Findings / Summary
- 10.2. Market Analysis – By Type
- 10.2.1. Acute Immune Thrombocytopenia
- 10.2.2. Chronic Immune Thrombocytopenia
- 10.3. Market Analysis – By Treatment
- 10.3.1. Thrombopoietin Receptor Agonists
- 10.3.2. Immunoglobulins
- 10.3.3. Corticosteroids
- 10.3.4. Others
- 10.4. Market Analysis – By Distribution Channel
- 10.4.1. Hospital Pharmacy
- 10.4.2. Retail Pharmacy
- 10.4.3. Others
- 11. France Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 11.1. Key Findings / Summary
- 11.2. Market Analysis – By Type
- 11.2.1. Acute Immune Thrombocytopenia
- 11.2.2. Chronic Immune Thrombocytopenia
- 11.3. Market Analysis – By Treatment
- 11.3.1. Thrombopoietin Receptor Agonists
- 11.3.2. Immunoglobulins
- 11.3.3. Corticosteroids
- 11.3.4. Others
- 11.4. Market Analysis – By Distribution Channel
- 11.4.1. Hospital Pharmacy
- 11.4.2. Retail Pharmacy
- 11.4.3. Others
- 12. U.K. Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 12.1. Key Findings / Summary
- 12.2. Market Analysis – By Type
- 12.2.1. Acute Immune Thrombocytopenia
- 12.2.2. Chronic Immune Thrombocytopenia
- 12.3. Market Analysis – By Treatment
- 12.3.1. Thrombopoietin Receptor Agonists
- 12.3.2. Immunoglobulins
- 12.3.3. Corticosteroids
- 12.3.4. Others
- 12.4. Market Analysis – By Distribution Channel
- 12.4.1. Hospital Pharmacy
- 12.4.2. Retail Pharmacy
- 12.4.3. Others
- 13. Italy Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 13.1. Key Findings / Summary
- 13.2. Market Analysis – By Type
- 13.2.1. Acute Immune Thrombocytopenia
- 13.2.2. Chronic Immune Thrombocytopenia
- 13.3. Market Analysis – By Treatment
- 13.3.1. Thrombopoietin Receptor Agonists
- 13.3.2. Immunoglobulins
- 13.3.3. Corticosteroids
- 13.3.4. Others
- 13.4. Market Analysis – By Distribution Channel
- 13.4.1. Hospital Pharmacy
- 13.4.2. Retail Pharmacy
- 13.4.3. Others
- 14. Spain Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 14.1. Key Findings / Summary
- 14.2. Market Analysis – By Type
- 14.2.1. Acute Immune Thrombocytopenia
- 14.2.2. Chronic Immune Thrombocytopenia
- 14.3. Market Analysis – By Treatment
- 14.3.1. Thrombopoietin Receptor Agonists
- 14.3.2. Immunoglobulins
- 14.3.3. Corticosteroids
- 14.3.4. Others
- 14.4. Market Analysis – By Distribution Channel
- 14.4.1. Hospital Pharmacy
- 14.4.2. Retail Pharmacy
- 14.4.3. Others
- 15. Rest of Europe Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 15.1. Key Findings / Summary
- 15.2. Market Analysis – By Type
- 15.2.1. Acute Immune Thrombocytopenia
- 15.2.2. Chronic Immune Thrombocytopenia
- 15.3. Market Analysis – By Treatment
- 15.3.1. Thrombopoietin Receptor Agonists
- 15.3.2. Immunoglobulins
- 15.3.3. Corticosteroids
- 15.3.4. Others
- 15.4. Market Analysis – By Distribution Channel
- 15.4.1. Hospital Pharmacy
- 15.4.2. Retail Pharmacy
- 15.4.3. Others
- 16. Asia Pacific Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 16.1. Key Findings / Summary
- 16.2. Market Analysis – By Type
- 16.2.1. Acute Immune Thrombocytopenia
- 16.2.2. Chronic Immune Thrombocytopenia
- 16.3. Market Analysis – By Treatment
- 16.3.1. Thrombopoietin Receptor Agonists
- 16.3.2. Immunoglobulins
- 16.3.3. Corticosteroids
- 16.3.4. Others
- 16.4. Market Analysis – By Distribution Channel
- 16.4.1. Hospital Pharmacy
- 16.4.2. Retail Pharmacy
- 16.4.3. Others
- 16.5. Market Analysis – By Country
- 16.5.1. Japan
- 16.5.2. China
- 16.5.3. India
- 16.5.4. South Korea
- 16.5.5. Australia
- 16.5.6. Rest of Asia Pacific
- 17. Japan Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 17.1. Key Findings / Summary
- 17.2. Market Analysis – By Type
- 17.2.1. Acute Immune Thrombocytopenia
- 17.2.2. Chronic Immune Thrombocytopenia
- 17.3. Market Analysis – By Treatment
- 17.3.1. Thrombopoietin Receptor Agonists
- 17.3.2. Immunoglobulins
- 17.3.3. Corticosteroids
- 17.3.4. Others
- 17.4. Market Analysis – By Distribution Channel
- 17.4.1. Hospital Pharmacy
- 17.4.2. Retail Pharmacy
- 17.4.3. Others
- 18. China Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 18.1. Key Findings / Summary
- 18.2. Market Analysis – By Type
- 18.2.1. Acute Immune Thrombocytopenia
- 18.2.2. Chronic Immune Thrombocytopenia
- 18.3. Market Analysis – By Treatment
- 18.3.1. Thrombopoietin Receptor Agonists
- 18.3.2. Immunoglobulins
- 18.3.3. Corticosteroids
- 18.3.4. Others
- 18.4. Market Analysis – By Distribution Channel
- 18.4.1. Hospital Pharmacy
- 18.4.2. Retail Pharmacy
- 18.4.3. Others
- 19. India Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 19.1. Key Findings / Summary
- 19.2. Market Analysis – By Type
- 19.2.1. Acute Immune Thrombocytopenia
- 19.2.2. Chronic Immune Thrombocytopenia
- 19.3. Market Analysis – By Treatment
- 19.3.1. Thrombopoietin Receptor Agonists
- 19.3.2. Immunoglobulins
- 19.3.3. Corticosteroids
- 19.3.4. Others
- 19.4. Market Analysis – By Distribution Channel
- 19.4.1. Hospital Pharmacy
- 19.4.2. Retail Pharmacy
- 19.4.3. Others
- 20. South Korea Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 20.1. Key Findings / Summary
- 20.2. Market Analysis – By Type
- 20.2.1. Acute Immune Thrombocytopenia
- 20.2.2. Chronic Immune Thrombocytopenia
- 20.3. Market Analysis – By Treatment
- 20.3.1. Thrombopoietin Receptor Agonists
- 20.3.2. Immunoglobulins
- 20.3.3. Corticosteroids
- 20.3.4. Others
- 20.4. Market Analysis – By Distribution Channel
- 20.4.1. Hospital Pharmacy
- 20.4.2. Retail Pharmacy
- 20.4.3. Others
- 21. Australia Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 21.1. Key Findings / Summary
- 21.2. Market Analysis – By Type
- 21.2.1. Acute Immune Thrombocytopenia
- 21.2.2. Chronic Immune Thrombocytopenia
- 21.3. Market Analysis – By Treatment
- 21.3.1. Thrombopoietin Receptor Agonists
- 21.3.2. Immunoglobulins
- 21.3.3. Corticosteroids
- 21.3.4. Others
- 21.4. Market Analysis – By Distribution Channel
- 21.4.1. Hospital Pharmacy
- 21.4.2. Retail Pharmacy
- 21.4.3. Others
- 22. Rest of Asia Pacific Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 22.1. Key Findings / Summary
- 22.2. Market Analysis – By Type
- 22.2.1. Acute Immune Thrombocytopenia
- 22.2.2. Chronic Immune Thrombocytopenia
- 22.3. Market Analysis – By Treatment
- 22.3.1. Thrombopoietin Receptor Agonists
- 22.3.2. Immunoglobulins
- 22.3.3. Corticosteroids
- 22.3.4. Others
- 22.4. Market Analysis – By Distribution Channel
- 22.4.1. Hospital Pharmacy
- 22.4.2. Retail Pharmacy
- 22.4.3. Others
- 23. Latin America Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 23.1. Key Findings / Summary
- 23.2. Market Analysis – By Type
- 23.2.1. Acute Immune Thrombocytopenia
- 23.2.2. Chronic Immune Thrombocytopenia
- 23.3. Market Analysis – By Treatment
- 23.3.1. Thrombopoietin Receptor Agonists
- 23.3.2. Immunoglobulins
- 23.3.3. Corticosteroids
- 23.3.4. Others
- 23.4. Market Analysis – By Distribution Channel
- 23.4.1. Hospital Pharmacy
- 23.4.2. Retail Pharmacy
- 23.4.3. Others
- 24. Middle East & Africa Immune Thrombocytopenia Market Analysis, Insights and Forecast, 2015-2026
- 24.1. Key Findings / Summary
- 24.2. Market Analysis – By Type
- 24.2.1. Acute Immune Thrombocytopenia
- 24.2.2. Chronic Immune Thrombocytopenia
- 24.3. Market Analysis – By Treatment
- 24.3.1. Thrombopoietin Receptor Agonists
- 24.3.2. Immunoglobulins
- 24.3.3. Corticosteroids
- 24.3.4. Others
- 24.4. Market Analysis – By Distribution Channel
- 24.4.1. Hospital Pharmacy
- 24.4.2. Retail Pharmacy
- 24.4.3. Others
- 25. Competitive Analysis
- 25.1. Global Market Share Analysis (2018)
- 25.2. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 25.2.1. Amgen Inc.
- 25.2.1.1. Overview,
- 25.2.1.2. Products & services,
- 25.2.1.3. SWOT analysis,
- 25.2.1.4. Recent developments,
- 25.2.1.5. strategies,
- 25.2.1.6. financials (based on availability)
- 25.2.2. Novartis AG
- 25.2.2.1. Overview,
- 25.2.2.2. Products & services,
- 25.2.2.3. SWOT analysis,
- 25.2.2.4. Recent developments,
- 25.2.2.5. strategies,
- 25.2.2.6. financials (based on availability)
- 25.2.3. Rigel Pharmaceuticals, Inc.
- 25.2.3.1. Overview,
- 25.2.3.2. Products & services,
- 25.2.3.3. SWOT analysis,
- 25.2.3.4. Recent developments,
- 25.2.3.5. strategies,
- 25.2.3.6. financials (based on availability)
- 25.2.4. Dova Pharmaceuticals
- 25.2.4.1. Overview,
- 25.2.4.2. Products & services,
- 25.2.4.3. SWOT analysis,
- 25.2.4.4. Recent developments,
- 25.2.4.5. strategies,
- 25.2.4.6. financials (based on availability)
- 25.2.5. Grifols S.A
- 25.2.5.1. Overview,
- 25.2.5.2. Products & services,
- 25.2.5.3. SWOT analysis,
- 25.2.5.4. Recent developments,
- 25.2.5.5. strategies,
- 25.2.5.6. financials (based on availability)
- 25.2.6. CSL Limited
- 25.2.6.1. Overview,
- 25.2.6.2. Products & services,
- 25.2.6.3. SWOT analysis,
- 25.2.6.4. Recent developments,
- 25.2.6.5. strategies,
- 25.2.6.6. financials (based on availability)
- 25.2.7. Octapharma AG
- 25.2.7.1. Overview,
- 25.2.7.2. Products & services,
- 25.2.7.3. SWOT analysis,
- 25.2.7.4. Recent developments,
- 25.2.7.5. strategies,
- 25.2.7.6. financials (based on availability)
- 25.2.8. Intas Pharmaceuticals Ltd.
- 25.2.8.1. Overview,
- 25.2.8.2. Products & services,
- 25.2.8.3. SWOT analysis,
- 25.2.8.4. Recent developments,
- 25.2.8.5. strategies,
- 25.2.8.6. financials (based on availability)
- 25.2.9. Saol Therapeutics
- 25.2.9.1. Overview,
- 25.2.9.2. Products & services,
- 25.2.9.3. SWOT analysis,
- 25.2.9.4. Recent developments,
- 25.2.9.5. strategies,
- 25.2.9.6. financials (based on availability)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
